|17-AAG||Unit size||Cat. code||Docs||Qty||Price|
17-Allylamino-17-demethoxygeldanamycin- An Hsp90 inhibitor
17-Allylamino-17-demethoxygeldanamycin (17AAG) is a less toxic and more stable analog of geldanamycin (GA) .
Even though 17-AAG binding to Hsp90 is weaker than GA,17-AAG displays similar antitumor effects as GA and a better toxicity profile.
17-AAG is currently in phase I clinical trial in several centers worldwide. Preliminary data obtained from these trials demonstrate that antitumor activity is achieved at concentrations below the maximum tolerated dose .
1. Schulte TW. & neckers LM., 1998. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42(4):273-9
2. Agnew Eb. et al. 2001. Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237-43
Working concentration: 10 nM - 10 μM
CAS number: 75747-14-7
Molecular weight: 586
Solubility: Soluble in DMSO (10 mg/ml)Back to the top
- 5 mg or 25 mg
17-AAG is shipped at room temperature.
Store lyophilized product at -20°C.
Protect from light.
Lyophilized productis stable for 6 months when stored properly.Back to the top